Related Experiment Video

Updated: Jun 17, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

A current review of targeted therapeutics for ovarian cancer

Susana M Campos1, Sue Ghosh

  • 1Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Journal of Oncology
|January 14, 2010
PubMed

Insights

Ovarian cancer is often detected late, and while initial treatments work, recurrence is common. New targeted therapies show promise for managing recurrent ovarian cancer beyond conventional options.

Area of Science:

  • Gynecologic Oncology
  • Medical Therapeutics
  • Cancer Research

Background:

  • Ovarian cancer frequently presents at advanced stages, posing a diagnostic challenge.
  • Current treatments targeting DNA replication and cell division show initial efficacy but often lead to recurrent disease.
  • Conventional therapies for recurrent ovarian cancer yield limited long-term benefits.

Purpose of the Study:

  • To review recent advancements in targeted therapeutics for ovarian cancer management.
  • To explore novel agents beyond conventional chemotherapy for recurrent disease.
  • To highlight emerging therapeutic strategies for improving patient outcomes.

Main Methods:

  • Review of scientific literature on ovarian cancer therapeutics.
  • Analysis of targeted agents including monoclonal antibodies and small molecule inhibitors.
  • Categorization of emerging therapies such as PARP inhibitors and pathway inhibitors.

Main Results:

  • Targeted therapies like bevacizumab (anti-VEGF) have been explored.
  • Various small molecule inhibitors targeting growth factor receptors are under investigation.
  • Emerging agents include folate receptor antibodies, triple angiokinase inhibitors, PARP inhibitors, and others targeting specific pathways.

Conclusions:

  • Significant progress is being made in developing targeted therapies for ovarian cancer.
  • Novel agents offer potential for improved management of recurrent and advanced disease.
  • Continued research into these diverse therapeutic strategies is crucial for overcoming treatment resistance.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...